- £218.75bn
- £236.77bn
- $54.07bn
- 78
- 14
- 98
- 73
REG - AstraZeneca PLC - Total Voting Rights
AnnouncementREG - AstraZeneca PLC - AstraZeneca Update on Anifrolumab in SLE
AnnouncementREG - AstraZeneca PLC - EC approves Bydureon BCise device for T2 diabetes
AnnouncementREG - AstraZeneca PLC - AstraZeneca PIIIb trial update for Bevespi in COPD
AnnouncementREG - AstraZeneca PLC - AZ's Tagrisso approved in Japan for 1st-line NSCLC
AnnouncementREG - AstraZeneca PLC - AstraZeneca prices a $3bn bond issue
AnnouncementREG - AstraZeneca PLC - EMA grants OD for selumetinib in NF1
AnnouncementREG - AstraZeneca PLC - Total Voting Rights
AnnouncementREG - AstraZeneca PLC - CHMP recommends Imfinzi for Stage III nsclc
AnnouncementREG - AstraZeneca PLC - AZN: H1 2018 Results
AnnouncementREG - AstraZeneca PLC - Atacand to be divested to Cheplapharm in Europe
AnnouncementREG - Circassia Pharma Plc AstraZeneca PLC - Holding(s) in Company
AnnouncementREG - AstraZeneca PLC - Holding(s) in Company
AnnouncementREG - AstraZeneca PLC - Total Voting Rights
AnnouncementREG - AstraZeneca PLC - Lynparza approved in Japan for BRCAm breast cancer
AnnouncementREG - AstraZeneca PLC - Imfinzi approved in Japan for Stage III nsclc
AnnouncementREG - AstraZeneca PLC - Bydureon receives positive CHMP opinion for BCise
AnnouncementREG - AstraZeneca PLC - AZ and Luye Pharma complete agreement for Seroquel
AnnouncementREG - AstraZeneca PLC - Lynparza: significant PFS 1st-line ovarian cancer
Announcement